BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Fate Therapeutics’ CRISPR-edited, iPSC-derived Cell Therapy Cleared for Clinical Investigation
Fate Therapeutics CRISPR Edited iPSC Therapy

Fate Therapeutics’ CRISPR-edited, iPSC-derived Cell Therapy Cleared for Clinical Investigation

May 29, 2020 By Cade Hildreth (CEO) Leave a Comment

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders, announced the U.S. FDA has cleared its Investigational New Drug (IND) application for FT538.

FT538 is the first CRISPR-edited, iPSC-derived cell therapy under development worldwide.

From a technical perspective, FT538 is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three functional components to enhance innate immunity.

These functional components include:

  1. A novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor;
  2. An IL-15/IL-15 receptor fusion (IL-15RF)
  3. The elimination of CD38 expression

Fate plans to begin clinical investigation of three weekly doses of FT538 as a monotherapy in acute myeloid leukemia (AML) and in combination with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma (MM).

Rooster DevServices

FT538 is the fourth off-the-shelf, iPSC-derived NK cell product candidate from Fate Therapeutic’s proprietary iPSC product platform to be cleared for clinical investigation by the FDA.

Overcoming COVID-19 related complications, the company has initiated the clinical manufacture of FT538 at its GMP facility in San Diego, California. To learn more, view the full announcement here.

bitbio

Source: Fate Therapeutics

To learn more, view the “Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2020.”iPS Cell Market Report

5/5 - (4 votes)

Filed Under: iPS Cells, Stem Cell News Tagged With: iPS cells

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.